The Clinical Utility of MPO / PON1 and MPO / HDL ‐C Ratios in Cardiovascular Risk Assessment
Therapeutic Apheresis and Dialysis · 2026-12 · 30 (6) · 971-972
DOI: 10.1002/1744-9987.70152 ↗Kurz gefasst
Leserbrief in der Zeitschrift Therapeutic Apheresis and Dialysis, online erschienen am 03.05.2026. Verfasst von Wei-Jia Meng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrated Chinese and Western Medicine, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, Zhejiang, China. Die Arbeit nennt 4 Literaturangaben. Gefördert von: Zhejiang Provincial College Students' Science and Technology Innovation Program.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Integrated Chinese and Western Medicine, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, Zhejiang, China.
ORCID-Profile: Sha-Sha Zhu
Förderung
- Zhejiang Provincial College Students' Science and Technology Innovation Program
Zitieren
APA
Meng, W. J., & Zhu, S. S. (2026). The Clinical Utility of MPO / PON1 and MPO / HDL ‐C Ratios in Cardiovascular Risk Assessment. Therapeutic Apheresis and Dialysis, 30(6), 971-972. https://doi.org/10.1002/1744-9987.70152
Vancouver
Meng WJ, Zhu SS. The Clinical Utility of MPO / PON1 and MPO / HDL ‐C Ratios in Cardiovascular Risk Assessment. Therapeutic Apheresis and Dialysis. 2026;30(6):971-972. doi:10.1002/1744-9987.70152
BibTeX
@article{Meng2026,
author = {Meng, Wei-Jia and Zhu, Sha-Sha},
title = {The Clinical Utility of MPO / PON1 and MPO / HDL ‐C Ratios in Cardiovascular Risk Assessment},
journal = {Therapeutic Apheresis and Dialysis},
year = {2026},
volume = {30},
number = {6},
pages = {971--972},
doi = {10.1002/1744-9987.70152}
}
EUVIMED